Medicare moves to pay for stroke thrombolytic therapy

Article

Hospitals will no longer lose money for thrombolizing stroke patients with tissue plasminogen activator (tPA).

Hospitals will no longer lose money for thrombolizing stroke patients with tissue plasminogen activator (tPA).

In midsummer, the Centers for Medicare and Medicaid Services unveiled DRG 559, a new code that pays $11,578 per case of acute ischemic stroke treated with a thrombolytic. Hospitals had previously been paid a flat rate of about $4000 to $6000 per case, regardless of whether thrombolytics were used.

"We have been barely breaking even for some time here," said Dr. Kieran Murphy, director of interventional neuroradiology at Johns Hopkins University. "Even though we have an excellent program in place that allows us to treat these patients appropriately, we've had to be very cautious, trying to lose as little money as possible."

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.